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Abstract
Background: Previous studies suggest that the responsiveness of TrkB receptor to BDNF is developmentally regulated in
rats. Antidepressant drugs (AD) have been shown to increase TrkB signalling in the adult rodent brain, and recent findings
implicate a BDNF-independent mechanism behind this phenomenon. When administered during early postnatal life, ADs
produce long-lasting biochemical and behavioural alterations that are observed in adult animals.
Methodology: We have here examined the responsiveness of brain TrkB receptors to BDNF and ADs during early postnatal
life of mouse, measured as autophosphorylation of TrkB (pTrkB).
Principal Findings: We found that ADs fail to induce TrkB signalling before postnatal day 12 (P12) after which an adult
response of TrkB to ADs was observed. Interestingly, there was a temporally inverse correlation between the appearance of
the responsiveness of TrkB to systemic ADs and the marked developmental reduction of BDNF-induced TrkB in brain
microslices ex vivo. Basal p-TrkB status in the brain of BDNF deficient mice was significantly reduced only during early
postnatal period. Enhancing cAMP (cyclic adenosine monophosphate) signalling failed to facilitate TrkB responsiveness to
BDNF. Reduced responsiveness of TrkB to BDNF was not produced by the developmental increase in the expression of
dominant-negative truncated TrkB.T1 because this reduction was similarly observed in the brain microslices of trkB.T1
2/2
mice. Moreover, postnatal AD administration produced long-lasting behavioural alterations observable in adult mice, but
the responses were different when mice were treated during the time when ADs did not (P4-9) or did (P16-21) activate TrkB.
Conclusions: We have found that ADs induce the activation of TrkB only in mice older than 2 weeks and that responsiveness
of brain microslices to BDNF is reduced during the same time period. Exposure to ADs before and after the age when ADs
activate TrkB produces differential long-term behavioural responses in adult mice.
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Introduction
Brain-derived neurotrophic factor (BDNF) and its receptor
TrkB are critical regulators of neuronal survival, differentiation,
axonal and dendritic growth, and synapse formation [1]. Within
the last years, their role in the adult central nervous system (CNS),
regulating functions such as neuronal plasticity, cognition, anxiety
and mood regulation, has been elucidated [2–5].
BDNF and TrkB play a central role in the mechanism of action
of antidepressant drugs (AD) [6,7]. All clinically used ADs rapidly
induce the autophosphorylation of TrkB and this TrkB activation
seems to be a common step in the mechanism of action of all ADs
[8,9]. Behavioural effects of ADs are blunted in animals with
reduced levels of BDNF or TrkB signalling in the CNS [8]. On the
other hand, infusion of BDNF into the adult brain or over-
expression of TrkB in neurons produces an AD-like behaviour in
rodents [10–12]. These data suggest that BDNF-TrkB signalling is
both necessary and sufficient for the AD-induced behavioural
effects in adult rodents.
Previous finding suggests that the responsiveness of TrkB to
BDNF is regulated during development; BDNF readily activates
TrkB in early postnatal rat brain microslices, but this effect of
BDNF is strongly blunted after the second week postnatally [13].
This finding is in contrast with the fact that BDNF levels in brain
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32869increase rapidly during this period [14], which corresponds to the
end of the period of the most intense neuronal migration and
differentiation.
Exposure to ADs during early life has been shown to produce
long-lasting behavioural changes in rodents that are evident even
in adulthood. Specifically, depressive and anxiety-like, motor and
sexual behaviours are modified in adulthood [15–17] and these
changes can be ameliorated by adult AD treatment [17]. AD
treatment during postnatal days 4–21 produces long-term changes
in bdnf and trkB mRNA expression in mice [17], which suggest that
BDNF-TrkB signalling may play a role in the long-term
behavioural consequences of AD treatment in early life.
We have here studied the phosphorylation response of TrkB to
systemic ADs and ex vivo BDNF at different stages of mouse
postnatal development. Our results suggest the intriguing
hypothesis that during the postnatal development, there is a shift
in TrkB responsiveness from a receptor that is readily activated by
BDNF but refractory to ADs to a TrkB clearly phosphorylated by
ADs but only weakly activated by BDNF. This shift may play a
role in the development of certain adult emotional phenotypes.
Results
Systemic imipramine treatment activates brain TrkB
signalling in an age-dependent manner
We have previously shown that a single intraperitoneal (i.p.)
injection of AD induces phosphorylation of TrkB within an hour
in the prefrontal cortex (PFC) and hippocampus (HC) of adult
rodent brain [8,9,18]. In this study, we treated mouse pups aged
between P5 and P21 with a single i.p. injection of either saline or
antidepressant imipramine (IMI; 30 mg/kg) and analyzed the
phosphorylation status of distinct tyrosine residues of TrkB at
30 min after the injection.
Our results showed that, along postnatal period, TrkB response
to ADs is age-dependently regulated. In the PFC, acute IMI
treatment of mice between P5 and P11 failed to increase TrkB
phosphorylation at the PLCc1 site (pY816) (Figure 1a). However,
a statistically significant increase of pY816-band immunoreactivity
was observed from P12 until adulthood in IMI treated animals
when compared to their saline treated controls (Figure 1a). In the
HC, TrkB response to acute IMI treatment presented a similar
activation pattern (Figure 1a). In both tissues, the magnitude of
phosphorylation of the Y816 during the late stage of postnatal
period was similar to the one observed in adult animals.
We have previously shown that ADs specifically induce
phosphorylation of TrkB at the PLCc1 site (Y816) and the
phosphorylation of CREB (cAMP response element binding
protein), the downstream target of this pathway, whereas no
increase in phosphorylation levels is observed at the Shc site
(pY515) or its downstream target Akt [9]. Consistent with this,
acute IMI treatment induced a significant increase in brain
pCREB levels in mice only after P13 (Figure 1b). This temporal
pattern of CREB activation closely followed that of TrkB
phosphorylation. IMI treatment also induced the association of
phosphorylated PLCc1 with catalytic TrkB receptors in P25
mouse pups whereas no such association was observed at P8
(Figure 1c–d). In contrast, IMI administration did not influence
the phosphorylation of Y515 site or Akt in PFC or in HC at any of
the age points investigated during the postnatal period (Figure
S1). Furthermore, as already reported in adult brain [9,18], acute
treatment with IMI did not regulate total protein levels of TrkB at
any age (data not shown).
Figure 1. Age-dependent effect of systemic imipramine on TrkB phosphorylation and signaling in the mouse brain. (a)
Phosphorylation of TrkB phospholipase-Cc1 (PLCc1) binding site (Y816) after acute imipramine treatment (30 mg/kg, 30 min, i.p.) in prefrontal cortex
(PFC) and hippocampus (HC). Phospho-TrkB values are normalized against total TrkB levels. (b) Phosphorylation of CREB (Ser
133) after acute
imipramine treatment (30 mg/kg, 30 min, i.p.) in prefrontal cortex (PFC) and hippocampus (HC). Phospho-CREB values are normalized against total
CREB levels. (c) The effect of acute imipramine treatment (30 mg/kg, 30 min, i.p.) on the association of phosphorylated PLCc1 (Tyr
783) with catalytic
TrkB receptors in P8 mouse pup hippocampus. (d) The effect of acute imipramine treatment (30 mg/kg, 30 min, i.p.) on the association of
phosphorylated PLCc1 (Tyr
783) with catalytic TrkB receptors in P25 mouse pup hippocampus. Results are expressed as percentage of respective
control. A t-test was performed between each control and treated group of animals at the different ages; *P,0.05, ** P,0.01, *** P,0.001. n=6–7
per group.
doi:10.1371/journal.pone.0032869.g001
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Knu ¨sel et al [13] reported that incubation of hippocampal and
cortical microslices prepared from rat pups up to the age of P7
respond to BDNF exposure with a robust increase in TrkB
phosphorylation. However, starting from P14 and in the adult
brain, this response of TrkB to BDNF is significantly reduced [13].
Consistent with these observations, incubation of fresh PFC and
HC microslices with BDNF elicited a strong increase of pTrkB
levels at P5 (Figure 2a). This response is still present at P9 and
P11 (Figure 2a). However, a clear decline in BDNF-induced
pTrkB levels was observed between P11 and P12 and only a
modest increase in pTrkB levels was detectable at P15 or after
(Figure 2a). The ability of BDNF to elicit phosphorylation of
TrkB in brain microslices prepared from adult mice (P60) was
completely abolished (Figure 2a), consistent with previous
findings [13]. After an acute treatment with BDNF no differences
were found in total protein levels of TrkB at any age (Figure S2).
The studies by Knu ¨sel et al [13] assayed the overall tyrosine
phosphorylation of TrkB after BDNF application, whereas we
have assayed the phosphorylation status of a specific tyrosine
residue in TrkB, the Y816 site. Consequently, we tested whether
also the other tyrosine residues in TrkB are hypo-responsive to
BDNF in late postnatal period. Indeed, significantly reduced
BDNF –induced phosphorylation of Y515 and Y705/6 (catalytic
domain) sites of TrkB was seen in hippocampal microslices
obtained from P24 mice but at P8 there was a clear induction in
both sites (Figure 2b). Essentially similar developmental hypore-
sponsiveness of Y515 and Y705/6 sites of TrkB was seen in
hippocampal microslices prepared from rat pups (P7-P27) (data
not shown).
The developmentally reduced ability of BDNF to induce TrkB
phosphorylation in the mouse brain microslices is probably not
due to reduced penetrance of BDNF into mature brain tissue since
a highly related neurotrophin, NGF (nerve growth factor), readily
induced TrkA phosphorylation (Y674/5) in hippocampal micro-
slices obtained from P24 mice (Figure 2c).
In order to examine the in vivo developmental responsiveness of
TrkB to BDNF, we analysed basal TrkB phosphorylation status in
the hippocampi of immature and adult mice with reduced BDNF
levels. In line with the ex vivo experiment, basal TrkB phosphor-
ylation at Y816 and Y705/6 sites was significantly reduced at P11
in Bdnf
+/2 mouse pups [19] when compared to age-matched wild-
type (WT) mice (Figure 3a). pTrkB levels were almost
undetectable in samples obtained from P11 Bdnf
2/2 mouse pup
hippocampi (Figure 3a). However, basal TrkB phosphorylation
levels were unaltered in adult mice with conditional deletion of
forebrain BDNF (cBdnf
2/2) [20] (Figure 3b). Moreover, and as
shown before [21], basal TrkB phosphorylation was unaltered in
the hippocampus of adult Bdnf
+/2 mice (Figure 3c).
Role of TrkB.T1 in regulating the responsiveness of TrkB
to BDNF and imipramine
Since the developmental increase in the expression of TrkB.T1,
the predominant truncated TrkB receptor, coincides with the
reduced responsiveness of TrkB receptor to BDNF [13], it has
been suggested that TrkB.T1, acting as dominant-negative partner
for full-length TrkB and as BDNF scavenging receptor [22,23],
might explain the reduced responsiveness of TrkB to BDNF
during late postnatal development [13]. We therefore investigated
the responsiveness of TrkB to BDNF and IMI treatments in WT
and trkB.T1
2/2 knock-out mice [24]. Incubation of brain
microslices with BDNF produced an age-dependent down-
regulation of TrkB phosphorylation levels from P10 to P20 in
both trkB.T1
2/2 knock-out and in WT mice (Figure 4a–b).
These data suggest that developmental increase in TrkB.T1
expression does not explain the developmental loss of TrkB
responsiveness to BDNF. Unexpectedly, basal TrkB phosphoryla-
Figure 2. Developmental regulation of BDNF-induced TrkB receptor phosphorylation. (a) Representative blots of experiments showing
age-dependent modification of BDNF-induced (50 ng/ml, 5 min, at 37uC) TrkB tyrosine phosphorylation (Y816) response in mouse cortical (PFC) and
hippocampal (HC) microslices ex vivo. (b) Representative blots of experiments showing that BDNF (50 ng/ml, 15 min, 37uC) readily induces TrkB
phosphorylation at sites Y515 and Y705/6 in P8 hippocampal microslices whereas neither site is effectively phosphorylated by BDNF in P24
hippocampal microslices. (c) NGF (50 ng/ml, 15 min, at 37uC) readily induces TrkA tyrosine phosphorylation (Y674/5) in P24 hippocampal microslices
whereas BDNF (50 ng/ml, 15 min, at 37uC) has no effect on TrkB phosphorylation (Y705/6) under the same conditions. For statistical analysis, a one-
way ANOVA followed with Bonferroni post hoc test was performed; ***P,0.001. n=4 per group. Phospho-TrkB values are normalized against total
TrkB levels.
doi:10.1371/journal.pone.0032869.g002
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2/2 knock-out hippocampal tissue was
significantly reduced compared to WT mice (Figure 4a). Acute
systemic IMI treatment produced an essentially similar increase in
TrkB phosphorylation in adult WT and trkB.T1
2/2 knock-out
mice (Figure 4c).
Potential facilitation of BDNF-TrkB signalling by
intracellular cAMP and antidepressants
Cyclic adenosine monophosphate (cAMP) signalling has been
shown to facilitate or ‘‘gate’’ BDNF-induced TrkB signalling in
mature hippocampal neurons in vitro [25]. ADs acutely increase
[cAMP]i levels via enhancing the synaptic levels of norepinephrine
(NE) and/or serotonin (5-HT) that subsequently can activate Gs –
linked postsynaptic receptors. Consequently, we next tested
whether acute treatment with IMI might restore the responsive-
ness of TrkB to BDNF ex vivo in adult hippocampus. As expected,
IMI treatment increased the pTrkB levels in the hippocampus but
no further phosphorylation was observed when BDNF was applied
(Figure 5a). We also decided to test the potential facilitatory effect
of cAMP on BDNF-TrkB signalling directly in ex vivo assay using
cell permeable cAMP phosphodiesterase resistant cAMP analog,
sp-cAMP. In microslices prepared from P24 mouse hippocampus
BDNF only slightly increased the phosphorylation status of TrkB
and this response was not further regulated by sp-cAMP pre-
incubation (Figure 5b).Essentially similar findings where ob-
served with hippocampal tissues derived from P20 mouse pups
(data not shown).
Long-term systemic treatment with antidepressant fluoxetine
has been shown to reopen developmental-like plasticity in the
adult rodent brain [26,27]. In view of this, we sought to examine
the responsiveness of TrkB to BDNF in the ex vivo assay in brain
microslices obtained from adult mice pre-treated with fluoxetine
(FLX) via drinking water (0.08 mg/ml) for 21 days [9,28]. In line
with our previous findings [9] long-term FLX treatment increased
TrkB phosphorylation in hippocampus but no further increase in
pTrkB levels was detected when the microslices were incubated
with BDNF (Figure 5c).
BDNF activates adult brain-derived TrkB in cell-free
kinase assay
We used an in vitro cell-free kinase assay to examine whether
there are any structural modifications in the TrkB receptor protein
itself that might prevent BDNF from binding to and activating
TrkB in the mature brain tissue. When the adult PFC and HC
homogenates were subjected to the kinase assay in the presence of
adenosine triphosphate (ATP, 100 mM), a clear increase in TrkB
phosphorylation in response to BDNF was observed (Figure 6a),
indicating that TrkB derived from adult brain was able to respond
to BDNF under cell-free conditions. Similarly, when P20
hippocampal tissues were subjected to the kinase assay, a robust
up-regulation of TrkB phosphorylation in response to BDNF was
observed (Figure 6b). However, ADs imipramine and fluoxetine
did not produce any increase in TrkB phosphorylation in the cell-
free kinase assay (Figure 6b). Imipramine and fluoxetine also
failed to alter TrkB phosphorylation when directly incubated with
P20 brain microslices in the ex vivo assay (Figure S3).
Differential long-lasting behavioural alterations after
early or late postnatal antidepressant
Exposure of rodents to ADs during postnatal life has been
shown to elicit alterations in emotional behaviour that are evident
in adulthood, long after the cessation of the treatment [15–
17,29,30]. We therefore tested whether the biochemical shift in
TrkB responsiveness to ADs brings about differential effects on
adult behaviour in response to postnatal treatment with ADs. Pups
were treated with either saline or a daily dose of AD clomipramine
(CLO) during two different time windows of the postnatal period:
an early postnatal stage (E-PS, from P4 to P9, when TrkB is not
responsive ADs) and a late postnatal stage (L-PS, from P16 to P21,
when TrkB is responsive to ADs) (Figure 7a). CLO was selected
Figure 3. Immature, but not adult, BDNF deficient mice show reduced basal hippocampal TrkB phosphorylation. (a) Basal
hippocampal TrkB phosphorylation (Y816, Y705/6) is significantly reduced in P11 old Bdnf
+/2 (+/2) and Bdnf
2/2 (2/2) mouse pups compared to age-
matched wild-type (WT) mice. (b) Basal hippocampal TrkB phosphorylation (Y816) is not altered in mice with conditional deletion of BDNF in the
forebrain (cBdnf
2/2 or (c) 2/2). (c) Basal hippocampal TrkB phosphorylation (Y705/6) is not altered in adult Bdnf
+/2 (+/2) mouse. For statistical
analysis, a t-test was performed; **P,0.01. n=3–6 per group. Phospho-TrkB values are normalized against total TrkB levels.
doi:10.1371/journal.pone.0032869.g003
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because of its prevalent serotonergic action. Furthermore, Vogel
and co-workers have extensively characterized the long-term
effects of early CLO treatment [15,29]. We found that CLO
activates TrkB with a similar developmental pattern to that
produced by IMI (Figure 7b). Furthermore, CLO treatment
during neither E-PS nor L-PS produced any changes in the levels
of BDNF or pTrkB in the HC or PFC of adult animals (data not
shown), suggesting that long-lasting alterations of the levels of
BDNF or TrkB do not explain the behavioural phenotype
observed in adult animals.
When we tested behaviour of adult animals at 3 months of age,
we found that animals exposed to CLO during E-PS or L-PS, long
before the behavioural testing, showed differential alterations in
exploratory locomotion and anxiety-related behaviour that
correlated with the age of AD treatment. Specifically, exposure
to CLO treatment produced strong long-term behavioural effects
in the Light-Dark test when the drug was given during the L-PS,
but not when it was administered during the E-PS (Table S1 and
Figure 7c). Two-way ANOVA revealed a significant main effect
of postnatal age x treatment interaction for the following
parameters: Distance in Dark (F[1,48]=8.94, p,0.05), Rearing
in Dark (F[1,48]=12.74, p,0.01), Total rearing (F[1,48]=8.09,
p,0.05), Ambulatory time in dark (F[1,48]=9.76, p,0.05), Total
resting time (F[1,48]=8.34, p,0.05), Stereotypics in dark
F[1,48]=7.79, p,0.05) and Total stereotypics (F[1,48]=8.53,
p,0.05). The post hoc test showed that mice exposed to L-PS CLO
show a significantly increased Time in the light (F[3,48]=3,056,
p,0.05, Figure 7c), Resting time in the light (F[3,48]=3,025,
p,0.05) and Total resting time (F[3,48]=3,329, p,0.01). On the
other hand, the same animals show reduced Time in the dark
(F[3,48]=3,209, p,0.05), Distance in light (F[3,48]=3,001,
p,0.05), Distance in dark (F[3,48]=3,457, p,0.01), Total
distance travelled (F[3,48]=2,870, p,0.05, Figure 7c), Rearings
in dark (F[3,48]=4,332, p,0.01), Total rearings (F[3,48]=2,850,
p,0.05), Ambulatory time in the dark (F[3,48]=3,195, p,0.01),
Total ambulatory time (F[3,48]=2,89, p,0.01, Figure 7c),
numbers of stereotypics in the dark (F[3,48]=5,082, p,0.01) and
total numbers of stereotypics (F[3,48]=4,464, p,0.01). No
statistical differences were found between numbers of entries in
the light, numbers of entries in the dark, total zone entries and
latency to the dark (Table S1).
In the novelty-suppressed feeding (NSF) test, only the
administration of CLO during the E-PS significantly influenced
adult behaviour. In this paradigm, food-deprived mice are
presented a food pellet in a novel environment and the latency
to approach the food is measured [31]. Two-way ANOVA
analysis showed a statistically significant effect for postnatal age
(F[1,48]=5,560, p,0.05) and treatment (F[1,48]=4,826,
p,0.05) (Table S1 and Figure 7d). The post hoc test showed a
reduced latency to feed in mice treated with CLO in the E-PS
when compared to control mice at the same age (p,0.05) (Table
S1 and Figure 7d). A small but significant effect was shown for
the home cage food consumption after the test for the postnatal
age variable (F[1,48]=5,266, p,0.05) (Table S1), but the post hoc
test did not show any difference among controls and CLO treated
animals. No differences were found between the groups for weight
loss before the test for postnatal age and treatment (Table S1).
Discussion
In the present study, we observed an age-dependent switch from
a TrkB receptor readily activated by BDNF but not by ADs during
early postnatal stage to a receptor activated by ADs but less
sensitive to direct ex vivo BDNF stimulation in late postnatal stage
and adulthood. AD exposure before or after this developmental
switch produces differential long-lasting effects on motor and
anxiety-like behaviours in adult animals. Although an inverse
temporal correlation between the appearance of the responsive-
ness of TrkB to systemic ADs and the robust reduction of BDNF-
induced TrkB phosphorylation in ex vivo microslices cannot be
taken as any evidence of causality, it is tempting to speculate that
the same maturation processes that bring about the AD
responsiveness, lead to developmental changes that restrict the
effects of BDNF on TrkB.
Figure 4. TrkB responsiveness to ex vivo BDNF and systemic
imipramine is not altered in trkB.T1
2/2 mice. BDNF-induced (ex
vivo, 50 ng/ml, 5 min) TrkB phosphorylation (Y816) in hippocampal
microslices prepared from P10 (a) or P20 (b) wild-type and trkB.T1
2/2
KO pups. (c) Imipramine-induced (30 mg/g, i.p., 30 min) TrkB phos-
phorylation (Y816) in adult male wild-type and trkB.T1
2/2 mouse
hippocampus. Two-Way ANOVA followed with Bonferroni post hoc test
was performed for statistical analysis; ** P,0.01, *** P,0.001 compared
to respective control, #P,0.05 compared to wt/control. The CTRL bar
represents control treatments at each age. Phospho-TrkB values are
normalized against total TrkB levels. n=3–5 per group.
doi:10.1371/journal.pone.0032869.g004
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study bind to and inhibit the monoamine reuptake pumps which
lead to enhanced monoamine receptor signalling. While mono-
aminergic neurons are among the first neurons to be generated
during early embryonic development, full maturation of these cells
extends beyond postnatal life in rodents [32,33]. Moreover, the
expression and function of several monoaminergic components
(receptors, reuptake pumps, and enzymes) are developmentally
regulated [32,33]. Thus, the long-lasting and differential behav-
ioural modifications produced by age-specific early AD exposures
given in this study may be explained by ongoing developmental
processes in monoaminergic systems, of which some aspects could
be regulated by enhanced TrkB-PLCc1-CREB signalling during
late, but not early postnatal stage. Nevertheless, these findings
need to be interpreted with caution and more specific manipu-
lations of monoaminergic systems during these specific develop-
mental time periods are required in future studies.
AD-induced TrkB phosphorylation during late postnatal period
takes place specifically at the Y816 (binding site of PLCc1), but not
at the Y515 (binding site of Shc), which is consistent to our
previous findings in adult brain [8,18]. Consequently, AD
treatment induced the interaction of phosphorylated PLCc1 with
TrkB receptors and the phosphorylation of CREB, but not that of
Akt [9], which is consistent of them being downstream mediators
of the PLCc1 and Shc pathways, respectively. Interestingly, CREB
activation in response to IMI treatment follows the same
developmental time course to that of pTrkB. CREB is considered
to play a critical role in AD drug responses [34] and pCREB
Ser133
is induced by a variety of signalling pathways, including PKA
(protein kinase A), Ca
2+-calmodulin kinase II and Mitogen-
activated protein kinase pathways [35]. Activation of the PKA
pathway through G-protein coupled monoamine receptors is
considered a central mechanism for CREB phosphorylation in
response to ADs [34]. The tight coupling of the developmental
time course of the responsiveness of TrkB and CREB to ADs
suggest that the activation of TrkB is a prerequisite for the CREB
phosphorylation by ADs.
We have here confirmed and extended the unexpected
observations previously reported by Knu ¨sel et al [13] demonstrat-
ing that incubation of brain microslices prepared from adult
rodent brain in the presence of BDNF fails to induce a pTrkB
response, while a robust autophosphorylation is observed in
microslices prepared from embryonic or early postnatal brain.
Under identical conditions, a closely related neurotrophin NGF
readily induced phosphorylation of its receptor TrkA in brain
microslices prepared from mature brain tissues, suggesting that the
dramatic reduction in the responsiveness of TrkB to BDNF in a
mature tissue is not related to a reduced penetrance of the
neurotrophin or to any general unsuitability of the assay for adult
brain tissues. Furthermore, basal TrkB phosphorylation status in
the hippocampus of BDNF deficient mice was significantly
reduced during early postnatal stage whereas adult BDNF
deficient mice showed no changes in pTrkB levels when compared
to control mice, as also reported before [21].
Figure 5. TrkB responsiveness to ex vivo BDNF is not altered by
antidepressant drugs or cAMP signalling. (a) P60 mice were
pretreated acutely with imipramine (Imi; 30 mg/kg i.p., 60 min) or saline
(Sal), hippocampi were collected, sliced and incubated ex vivo with or
without BDNF (50 ng/ml) for 5 minutes at 37uC. TrkB phosphorylation
(Y816) was analyzed with western blotting. (b) P24 hippocampal
microslices were pre-incubated at 37uC for 15 minutes with vehicle or
sp-cAMP (10 mM) and then exposed to BDNF (50 ng/ml) or vehicle at
37uC for another 15 minutes. TrkB phosphorylation (Y705/6) was
analyzed with western blotting. (c) Adult animals were chronically
treated for 21 days with vehicle (Veh) or fluoxetine (0.08 mg/ml) in
drinking water, hippocampi were collected, sliced and incubated ex vivo
with or without BDNF (50 ng/ml) for 5 minutes at 37uC. TrkB
phosphorylation (Y816) was analyzed with western blotting. Phospho-
TrkB values are normalized against total TrkB levels. Two-Way ANOVA
followed with Bonferroni post hoc test was performed for statistical
analysis; **P,0.01, *** P,0.001. n=3–6 per group.
doi:10.1371/journal.pone.0032869.g005
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increase in the truncated TrkB.T1 receptor that can act as
dominant-negative partner for full-length TrkB, might explain the
specific reduction of the responsiveness of TrkB to BDNF. We
ruled out this possibility, since hippocampal TrkB receptors
responded similarly to BDNF and ADs in the tissue samples
prepared from WT and trkB.T1
2/2 mice. Another possible
explanation could be that the ability of BDNF to induce TrkB
activation in the mature brain depends on additional gating
mechanisms such as cAMP or adenosine [25,36]. To test this
possibility, we investigated whether systemic AD treatment, which
is known to activate [cAMP]i signalling, might facilitate or restore
the ability of BDNF to activate TrkB, but this did not turn out to
be the case. Moreover, direct up-regulation of [cAMP]i signalling
in the ex vivo assay failed to facilitate BDNF-induced TrkB
phosphorylation in mature microslices. It is possible that functional
maturation of neuronal networks and closure of sensitive periods
may modify the responsiveness of TrkB to BDNF (and ADs).
Chronic treatment with AD fluoxetine has been shown to reopen
developmental-like plasticity in the adult rodent cortex [26], but
also this treatment failed to facilitate the responsiveness of TrkB to
ex vivo BDNF in the adult mouse brain. However, the cell-free
TrkB kinase assay suggests that there does not appear to be any
structural modifications in the TrkB protein itself that would
prevent the receptor from binding to and being activated by
BDNF.
The reason for and significance of the apparently complete loss
of TrkB responsiveness to BDNF (also to high concentrations, see
[13]) in an ex vivo assay after early postnatal life remains unclear.
Although recent evidence suggest that lack of BDNF has only
minor effects on the survival and structure of cortical neurons in
the CNS [37], BDNF has, nevertheless, well characterized actions
in the adult CNS. For example, loss of BDNF produces clear
behavioural effects in adulthood [20,38,39]. In addition, in vivo
infusion of BDNF into the adult brain increases TrkB phosphor-
ylation, albeit only at relatively high concentrations [40], and
produces distinct behavioural responses depending on the site of
injection [10,11,41] and at least part of these effects are mediated
via TrkB [11]. Furthermore, we have observed an essentially
identical loss of behavioural responses to ADs in both bdnf
+/2 mice
and in mice over-expressing an inhibitory form of trkB (TrkB.T1)
in brain [8], clearly implicating the BDNF-TrkB signalling in this
response. Thus, even though the mechanisms responsible for this
discrepancy remain unclear and require further studies, these
results clearly demonstrate that a change in TrkB responsiveness
takes place during brain maturation at around 2 weeks of age in
mice.
Previous studies have demonstrated that exposure of rodents to
different ADs during early postnatal development brings about
long-lasting biochemical and behavioural effects which can be
observed in adult animals, long after the drug has disappeared
from the body [15–17,29,30]. In view of the differential
developmental responsiveness of TrkB to ADs during postnatal
age we sought to examine potential long-lasting behavioural
alterations produced by sub-chronic CLO treatment during the
period when the drug does or does not activate TrkB (P16-21 or
P4-9, respectively). Interestingly, we found that mice treated with
CLO during the P4-9 show long-lasting behavioural changes in
the novelty suppressed feeding test that were not observed in
animals treated during the P16-21. Conversely, the light dark test
revealed long-lasting behavioural alterations that were observed
only in mice treated with CLO during P16-21.
In conclusion, our present data suggest the intriguing hypothesis
that in rodents, TrkB shows contrasting responsiveness to BDNF
and ADs during the postnatal maturation and that this regulation
may have important repercussions on the development of an adult
behavioural phenotype.
Materials and Methods
Animals
Male C57BL/6JRccHsd mice (Harlan Laboratories, Nether-
lands), trkB.T1
2/2 [24], Bdnf
+/2/Bdnf
2/2 [19] or BDNF
2L/2LCk-cre
[20] and their wild-type littermates were used for the studies. The
Figure 6. BDNF, but not antidepressant drugs, induce TrkB phosphorylation in a cell-free kinase assay. (a) Incubation of adult cortical
or hippocampal brain lysates with BDNF (50 ng/ml) induces the tyrosine phosphorylation of Shc (Y515) and phospholipase-Cc1 (Y816) binding sites
of TrkB. * indicate unidentified phospho-proteins detected by the antibodies. (b) BDNF (50 ng/ml), but not imipramine or fluoxetine, induces TrkB
phosphorylation in P20 mouse hippocampal lysates. Overall tyrosine phosphorylation of TrkB was analyzed using phospho-TrkB ELISA. For statistical
analysis, a one-way ANOVA followed with Bonferroni post hoc test was performed; ***P,0.001 compared to respective control, ###P,0.001
compared to ATP/Control. n=4 per group.
doi:10.1371/journal.pone.0032869.g006
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12 h light-dark cycle, lights on at 6 A.M.). All the experiments were
carried out according to the guidelines of the Society for
Neuroscience and were specifically approved by the County
Administrative Board of Southern Finland (Permit: ESLH-2007-
09085/Ym-23).
Experimental Design
Postnatal acute antidepressant treatments. Dams with
their litters were housed individually. For postnatal acute
antidepressant treatments, age-matched litters (P5-21) were
randomly assigned to receive i.p. injection of saline (SAL) (NaCl
0.9%, 5 ml/kg), imipramine (IMI) (HCl salt, dissolved in SAL,
30 mg/kg, 5 ml/kg; Sigma-Aldrich Finland Oy, Helsinki), or
clomipramine (HCl salt, dissolved in SAL, 20 mg/kg, 5 ml/kg;
Sigma-Aldrich) and following indicated lag-time (30–60 min)
hippocampus and medial prefrontal cortex were collected as
described in [9]. Briefly, mice were stunned with CO2, the brains
quickly removed and bilateral hippocampus and prefrontal cortex
were dissected out on a dish cooled on dry-ice. Samples were
homogenized in a NP++ buffer (300 ml/sample; composition:
137 mM NaCl, 20 mM Tris, 1% NP-40, 10% glycerol, 48 mM
NaF, H2O, 26 Complete inhibitor mix (Roche) and 2 mM
Na3VO4). After incubation on ice for 15 min, samples were
centrifuged (16100 g, 15 min, +4uC) and the supernatant collected
for further analysis.
Postnatal sub-chronic clomipramine treatment. Dams
with their litters were housed individually. The litters were
randomly assigned to 4 groups: saline injected (SAL) (NaCl 0.9%,
5 ml/kg), and clomipramine injected (CLO) (dissolved in SAL,
20 mg/kg, 5 ml/kg) [16], starting at postnatal day 4 (P4) until P9
(Early-Postnatal Stage, E-PS), and from P16 to P21 (Late-Postnatal
Stage, L-PS). Each pup was weighted and injected once daily
(between 9 A.M.–11 A.M.). During the treatment the litter was
removed from its home cage and placed in a bucket with some
shavings of their home cage. All the pups belonging to a single
litter were injected randomly in less than 3 minutes. After the
injection the pups were immediately placed back in their home
cage. CLO treatments did not have any significant effect on the
weight gain of the pups and later in adulthood (Figure S4).
Mice were weaned on P22 and males were housed together (4–6
mice/cage) until the behavioural experiments. For biochemical
Figure 7. Postnatal systemic clomipramine treatments lead to long-lasting and distinct behaviours depending onexposure period.
(a) Schematic figure showing treatment groups. Animals were treated with a daily dose of clomipramine (20 mg/kg, i.p.) during early (P4-9; E-PS) or
late (P16-21; L-PS) postnatal period. At 3 months of age the animals were subjected to behavioural analyses (b) Age-dependent phosphorylation of
TrkB receptor (Y816) in mouse brain after acute treatment with clomipramine (20 mg/g, i.p., 60 min). (c) Clomipramine treatment during late
postnatal period (activates TrkB) produces anxiolytic-like behaviour in the light-dark test. (d) Clomipramine treatment during the early postnatal
period (does not activate TrkB) produces anxiolytic-like behaviour in the novelty-suppressed feeding task. A t-test (b) or Two-Way ANOVA followed
with Bonferroni post hoc test (c–d) was performed for statistical analysis; *P,0.05, ** P,0.01, *** P,0.001 compared to the respective age saline (Sal)
treated group. The CTRL bar is representative of each respective control at each age. n=6/group (biochemical analysis) or n=10–15 per group
(behavioural analysis).
doi:10.1371/journal.pone.0032869.g007
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behavioural test and their tissues were collected and processed as
described before.
Adult antidepressant treatment. For the acute AD
treatments, adult (,P90) mice received a single i.p. injection of
imipramine (dissolved in SAL, 30 mg/kg, 5 ml/kg) or SAL and
were killed 30 minutes after. For chronic AD treatment, adult
(,P90) mice had free access to either tap water or to 0.08 mg/ml
solution of fluoxetine (FLX; HCl salt; Orion Pharma, Turku,
Finland) for 21 days [9,28]. On the final day of treatment the
animals were killed. Hippocampus and prefrontal cortex samples
were rapidly dissected out and processed as described before.
Ex vivo assays
The ex vivo BDNF stimulation assay was performed according to
Knu ¨sel et al [13] with slight modifications. Mouse hippocampi and
medial prefrontal cortex at different ages were dissected. After
dissection the samples were placed on a filter paper wet with cold
Neurobasal Medium (NBM) (Neurobasal medium (Gibco), 2%
B27 supplement (Gibco), 0.5 mM Glutamine (Gibco) and
penicillin/streptomycin (Sigma), and then the tissues were sliced
into equally sized pieces. The slices were transferred in fresh tubes
and washed twice with NBM +10% heat-inactivated Fetal Calf
Serum (FCS) (Gibco). Tissues were gently re-suspended with a
Pasteur pipette. The medium was removed and 600 ml of NBM
+10% FCS with or without BDNF (Peprotech) or NGF (Promega)
were added. The tubes were closed and incubated at +37uC for 5
or 15 minutes gently shaking. Finally the tubes were put on ice,
spun down, the medium removed, the pellet was rinsed once with
PBS and then the samples were homogenized in NP++ buffer. A
set of samples were pre-incubated with cAMP analog sp-cAMP
(10 mM; Sigma-Aldrich) for 15 minutes at +37uC before BDNF
stimulation.
TrkB kinase activity assay
Assays were performed according to the procedures described
by Angeles et al [42] with some modifications. Each assay was
performed in a final volume of 20 mL of 50 mM Hepes pH 7.4,
140 mM NaCl, 10 mM MnCl2, 0.05% BSA, 2% DMSO with or
without 100 mM ATP and/or 50 ng/mL BDNF. The reaction was
initiated adding 40 mgo fN P ++ lyzed protein extract to the mix
and the incubation was allowed to proceed for 10 min at 37uC.
For a subset of samples, the reaction was quenched by adding an
equal volume of 46 Laemmli sample buffer and proteins were
separated by SDS-PAGE and TrkB phosphorylation status
analyzed with western blotting as described below. Rest of the
samples we immediately transferred to Trk antibody containing
ELISA (enzyme-linked immunosorbent assay) plates, 3% BSA/
PBS-T (+2m MN a 3VO4) added ad 200 ml, and phospho-TrkB
ELISA proceeded as previously described [18].
Immunoprecipitation and western blot
Sample protein concentrations were measured using the Lowry
Method (Bio-Rad DC protein assay). Lectin precipitation was
carried out essentially as described [9] using Wheat Germ
Agglutinin (EY Laboratories, San Matteo, CA, USA). TrkB
immunoprecipitation was carried out using a TrkB specific
antibody (5 ml/sample; #AF1494, R&D Systems Europe, Abing-
don, UK) in conditions described in [9]. Proteins were separated
in a SDS-PAGE under reducing conditions and blotted to a PDVF
membrane (300 mA for 1 h at 4uC). Membranes were incubated
with the following primary antibodies: anti-p-TrkB
Y816 (1:5000;
kind gift from Dr. M. Chao, Skirball Institute, NY, USA), anti-p-
TrkA/B
Y490/Y515 (#9141; 1:2000; Cell Signalling Technology
(CST), MA, USA), anti-p-TrkA/B
Y674-5/Y705-6 (1:1000; CST),
anti-TrkBout (#610102; 1:2000; RD Transduction Laboratories,
Franklin Lakes, NJ USA), anti-p-CREB
S133 (#9198; 1:1000;
CST), anti-CREB (sc-186; 1:100, Santa Cruz Biotechnology
(SCB), CA, USA), anti-p-Akt
Thr308 (#9275; 1:2000, CST), anti-
AKT (#4691; 1:1000, CST), anti-p-PLCc1
Y783 (#2821, 1:1000,
CST) or anti-Trk (#sc-11 (rabbit), 1:1000, SCB). Further the
membranes were washed with TBS/0.01% TweenH (TBST) and
incubated with horseradish peroxidase conjugated secondary
antibodies (1:10000 in non fat dry milk, 1 h, RT, Bio-Rad
Laboratories, Hercules, CA). After subsequent TBST washes,
secondary antibodies were visualized using electrochemilumines-
cence kits (Amersham Biosciences) followed by an exposure to Fuji
LAS-3000 Camera (Tamro Medlabs, Vantaa, Finland) for ECL
detection.
Behavioural tests
Battery of behavioural tests [43] were performed on adult male
E-PS, L-PS and control mice, starting from P90. The tests were
done between 9 A.M.-3 P.M. with at least 3 days of interval
between each test. Exploratory locomotion, depression- and
anxiety-like behaviours were assessed by the following tests:
light-dark test, elevated plus maze, open-field test, forced swim
test and novelty-suppressed feeding test. The tests were performed
in this order in a period of 3 weeks [43]. Among all these tests, only
the light-dark test and the novelty-suppressed feeding test showed
statistically significant differences between the drug and saline
treated groups, and only these two tests are described in more
detail in this manuscript.
Light-Dark Test (LD). Testing was performed for 10 min in
an acrylic cage (28.5628.5620 cm) (TSE, Bad Homburg,
Germany) divided into two equal sized compartments: one part
with transparent walls, open topped and brightly illuminated
(,450 lx by a 40 W light bulb fixed 55 cm above the floor), the
other part made from black plastic (passing infrared light) and
covered by a lid. The two compartments were separated by a
partition containing an opening (765 cm) in its centre at floor
level. The animal was placed in the centre of the light
compartment facing away from the opening, and the latency to
enter dark area, time spent in the compartments, total distance
travelled, immobility time and the number of entries to dark were
measured over 10 min. In addition, rearing time was also
calculated. Testing apparatus was thoroughly cleaned before
each animal using 70% ethanol.
Novelty-Suppressed Fedding. Novelty-Suppressed Feeding:
The Novelty-Suppressed Feeding (NSF) was performed as
previously described [30]. Briefly, the test was performed in
brightly lit (800–900 lux) open arena (51635 cm). A small piece of
filter paper with a pre-weighted food pellet was placed in the
middle of the arena. The animals were deprived of food for 24 h
with water available ad libitum. On testing day each animal was
removed from its home cage and placed in a holding cage for
30 min before the test and then put in one corner of the arena.
The latency to beginning of a feeding episode was measured
(maximum over a period of 5 min). Immediately, after starting of
feeding the mouse was removed from the arena and placed with
the food pellet in its home cage and allowed to feed ad libitum over
a period of 5 min. The amount of food consumed was quantified
by weighting the pellet.
Data analysis
Immunoblot bands were quantified using NIH ImageJ. All the
data are expressed as mean 6 SEM (Standard Error of Mean) and
as percentage of control. Statistical analyses were performed using
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Diego California USA). For comparison between two groups Two-
way Student’s t-test was used. Two-way ANOVA or two-way
ANOVA for repeated measures was used to reveal main effect and
interaction between the factors followed by Bonferroni post hoc test.
The criterion for significance was set to p,0.05.
Supporting Information
Figure S1 Effect of imipramine on the phosphorylations
of TrkB Shc binding site and Akt during development. (a)
Phosphorylation of TrkB Shc binding site (Y515) after acute
imipramine treatment (30 mg/kg, 30 min, i.p.) in prefrontal
cortex (PFC) and hippocampus (HC). (b) Phosphorylation of Akt
(Thr
308) after acute imipramine treatment (30 mg/kg, 30 min, i.p.)
in prefrontal cortex (PFC) and hippocampus (HC). Phospho-
protein values are normalized against corresponding total protein
levels. Results are expressed as percentage of respective control. A
t-test was performed between each control and treated group of
animals at the different ages. n=6–7 per group.
(TIF)
Figure S2 Acute BDNF stimulations does not regulate
total TrkB protein levels in brain microslices. Represen-
tative blots showing the levels of full-length TrkB after control or
BDNF stimulation in cortical (PFC) or hippocampal (HC)
microslices prepare from P5-P60 old mice.
(TIF)
Figure S3 Imipramine and fluoxetine does not directly
induce TrkB phosphorylation in hippocampal micro-
slices ex vivo. P20 hippocampal microslices were incubate with
vehicle or different concentrations of imipramine (Imi; 1–100 mM)
(a) or fluoxetine (Flx; 1–100 mM) (b) for 15 min at 37uC and TrkB
phosphorylation (Y705/6) analyzed with western blotting. n=3
per group.
(TIF)
Figure S4 The effect of postnatal clomipramine on
weight gain of mouse. A daily dose of clomipramine
(20 mg/kg, i.p.) or saline during early (P4-9; E-PS) or late (P16-
21; L-PS) postnatal period produced no changes on weight gain
during (P4-21) (a) or after the treatments (P28-120) (b). n=10–15
per group.
(TIF)
Table S1 Postnatal treatments with clomipramine lead
to long-lasting and distinct behaviours depending on
early exposure period. The effect of early (postnatal days 4–9)
and late (postnatal days 16–21) postnatal clomipramine treatment
(20 mg/kg, i.p., once daily) on behaviour in light-dark box test and
novelty suppressed feeding test in adult (P90) animals. Two-Way
ANOVA followed with Bonferroni post hoc test was performed for
statistical analysis; *P,0.05, ** P,0.01. n=10–15 per group.
(DOCX)
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